BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-308@pharmaconomics
DTSTAMP:20260707T034253Z
DTSTART;VALUE=DATE:20260531
DTEND;VALUE=DATE:20260601
SUMMARY:SMMT Phase 1 — ivonescimab
DESCRIPTION:Phase 1 trial results for ivonescimab in non-small cell lung cancer (NSCLC) are due May 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000037/a2026_prx0506xq12026earn.htm\n\nTrack it: https://www.pharmaconomics.com/e/308
URL:https://www.pharmaconomics.com/e/308
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SMMT catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR